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1  |  INTRODUC TION
Over the last few decades, anticancer treatments such as chemo-
therapy and radiotherapy have led to a significant decrease in the 
mortality rate among pediatric and young adult women. An an-
nual decline in mortality of 1.5% is observed in the United States.1 
However, an improvement in the survival rate must be accompanied 
by a reduction in the side effects of treatment and an enhancement 
in the quality of life of survivors of cancer. Unfortunately, alteration 
of ovarian function and development of premature ovarian insuffi-
ciency (POI) are frequent consequences of anticancer treatments.
Consequently, fertility preservation programs have been devel-
oped for adolescent and young adult (AYA) survivors of cancer in re-
cent years. The American Society of Clinical Oncology was the first 
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Background: Preservation of female fertility is a relatively new field in medicine that 
has grown very rapidly in recent decades. At the beginning, embryo freezing remained 
the most effective technique. Thereafter, cryopreservation of oocytes and ovarian 
tissue was considered a secure tool in human fertility preservation. Storage of cortical 
ovarian tissue is moreover relevant for children, prepubertal girls, and adult patients 
who cannot benefit from cryopreservation of oocytes.
Objective: To analyze and review recent and relevant scientific literature on medical 
and social reasons for preservation of fertility.
Methods: The review was conducted based on articles identified from PubMed data-
bases using keywords.
Main results: Oocyte vitrification allows women to preserve their fertility without the 
need for fertilization. Nowadays, thousands of healthy children have been born from 
this procedure. Occurrence of pregnancy depends on two main factors: the number 
of mature oocytes in storage and the age of the patient at the time of vitrification. 
Numerous adaptations have been developed to suit the ovarian stimulation regiments 
to patients with cancer. In young prepubertal girls, freezing of ovarian tissue remains 
the best and only option.
Conclusion: Oocyte vitrification therefore appears to be the gold standard technique 
of preserving fertility in young women.
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society to publish guidelines concerning ovarian toxicity of cancer 
treatments and the possibilities of preserving fertility.2 Since then, 
many other international scientific societies have also published rec-
ommendations on this subject.
Different techniques for the preservation of fertility have been 
developed in recent years. The most appropriate technique for a 
given patient depends on multiple parameters, including the type 
of pathology, the treatment required, the urgency of treatment, the 
age of the patient, and the presence or absence of a partner.
In pathologies treated by radiotherapy only, oophoropexy may 
be proposed to remove the ovary from the radiation field.3 For some 
diseases requiring chemotherapy with moderate gonadotoxicity, 
such as breast cancer, administration of gonadotropin- releasing 
hormone (GnRH) analogs was proposed in order to suppress ovarian 
activity.4
In some cases, severe ovarian toxicity cannot be avoided, and 
cryopreservation of gamete or gonadal tissue must be proposed to 
preserve the patient's fertility. In women, vitrification of a mature 
oocyte after controlled ovarian stimulation (COS) or cryopreserva-
tion of ovarian tissue are the two best options available. When the 
risk of amenorrhea in the patient is high, clinicians can combine two 
or even three methods of fertility preservation.5,6
Moreover, the techniques for fertility preservation can be pro-
posed to other patients at risk of POI regardless of the underlying 
cause (neoplasia, benign pathology as endometriosis,7 or simply 
aging ovarian dysfunction).
2  |  MATERIAL S AND METHODS
The present review provides a literature overview on current knowl-
edge about techniques used to preserve female fertility in case of 
medical and non- medical indications or in banking of donor eggs.
2.1  |  Search strategy
The PubMed database (National Library of Medicine, https://pub-
med.ncbi.nlm.nih.gov/) was searched up to February 2021. A com-
bination of Medical Subject Headings (MeSH) descriptors has been 
used: “oocyte vitrification” and “fertility preservation” or “ovarian 
stimulation” or “ovarian tissue” or “pregnancy.”
2.2  |  Screening of publications
A search using the specific MeSH resulted in hundreds of publica-
tions. One of the first co- authors (LH) performed a global screen-
ing based on title, authors, and year of publication in order to select 
data likely to enhance understanding of and updating the topic of 
interest. Abstracts from the selected papers were read by the two 
first co- authors and articles recognized as relevant by both were 
analyzed in more detail.
2.3  |  Data synthesis
A total of 36 references consisting of reviews, clinical studies, guide-
lines, and recommendations published between 2005 and 2021 
were selected to document the present work. The collected data 
were organized as a literature review synthesis structured on para-
graphs and sub- paragraphs.
3  |  INDIC ATIONS FOR PRESERVATION OF 
FEMALE FERTILIT Y
3.1  |  Malignant diseases
Malignant diseases treated by surgery, chemotherapy, or radio-
therapy associated with POI are good indications for preservation 
of fertility.
The impact of chemotherapy depends on several parameters, in-
cluding the nature of the agent used, the dose and duration of admin-
istration, and the patient's age at the time of treatment. Alkylating 
agents, such as cyclophosphamide, have a very pronounced go-
nadic toxicity by inducing massive follicular loss. It is obvious that 
the higher the dose used, the higher the toxicity. Follicular loss can 
also be increased when several chemotherapy agents need to be 
combined. The impact on gonadal function can be reversible or irre-
versible. While temporary amenorrhea results from the destruction 
of mature follicles, definitive amenorrhea can arise from the loss of 
primordial follicles.3
Radiotherapy can also induce infertility. The impact on ovarian 
tissue depends on the cumulative dose administered but also on the 
fractionation of doses and the irradiation site. Treatment in the pel-
vic field is very likely to induce POI, with an irradiation dose of less 
than 2 Gy resulting in the destruction of half of immature human 
follicles.8 Total body irradiation causes infertility in 90% of patients. 
Beside follicular loss, radiotherapy can induce major tissue remod-
eling such as ovarian stroma fibrosis or extensive vascular damage 
following tissue hypoxia. Ovarian atrophy may therefore arise, re-
sulting in tissue dysfunction.9 Cerebral irradiation, particularly in 
the hypothalamic- pituitary zone, may also induce infertility by hy-
pogonadotropic hypogonadism. Radiotherapy also has deleterious 
effects on the myometrium, especially in prepubertal children who 
are particularly sensitive.
The age of the patient plays an important role in the ovarian tox-
icity of radiotherapy. Older women are at a higher risk of POI due to 
the physiological decrease in the number of follicles and degradation 
of quality over time. At birth, irradiation of 20 Gy is needed to cause 
sterility in 97% of patients, while the same effect is observed with 
18, 16, and 14 Gy in patients aged 1, 20, or 30 years.3
Nevertheless, the probability of POI depends on the intrin-
sic ovarian reserve, which varies considerably from one patient to 
another.
The most frequent indications for oncologic preservation 
of fertility are hematologic pathologies (Hodgkin's lymphoma, 
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non- Hodgkin's lymphoma, and leukemia) and breast cancers. Other 
indications include sarcoma, colorectal cancer, borderline ovarian 
tumors, and central nervous system malignancies among others.10 In 
many countries, different strategies for the preservation of fertility 
are allowed. For example, in Belgium, women and men aged under 
38 and 45 years, respectively, are reimbursed in case of malignant 
disease.
3.2  |  Benign diseases
The preservation of fertility must also be proposed to patients at risk 
of POI due to benign conditions and their treatments, such as au-
toimmune or hematological disorders requiring chemotherapy and 
bone marrow transplantation.
Some ovarian pathologies can also impair fertility, such as the 
presence of bilateral ovarian tumors, severe or recurrent ovarian 
endometriosis, and recurrent ovarian torsion. Genetic predisposi-
tion to premature depletion of the ovarian reserve is also a good 
indication for the preservation of fertility10 (e.g. blepharophimosis, 
ptosis, and epicanthus inversus syndrome [BPES], autoimmune poly-
endocrinopathies, and some enzyme deficiencies), although preser-
vation of fertility may be controversial in some cases such as Turner 
syndrome.11
3.3  |  AGE- Banking, oocyte donation, and 
transgenders
“AGE- Banking” relates particularly to preservation of gametes un-
dertaken for personal reasons or in order to anticipate natural ex-
haustion. This concept has emerged in recent decades as women's 
age at the time of first pregnancy has been progressively rising world-
wide. Lack of a stable partner, financial reasons, self- realization, and 
career status are some of the factors that convince women to post-
pone childbearing.10 Consequently, the cryopreservation of oocytes 
increases their chances of conceiving their own genetic offspring.
Cryopreservation of oocytes also ensures accessibility for in-
fertile women to oocyte donation programs and preservation of 
fertility in transgender people before their medical and surgical 
transition.12,13
4  |  CRYOPRESERVATION OF OOCY TES
Vitrification of oocytes is now a routine technique available world-
wide for women who wish to preserve their fertility. The European 
Society of Human Reproduction and Embryology recently published 
a guideline on the preservation of female fertility 14 and a part of 
this working group, specialized in the cryopreservation of oocytes, 
reported a total of 34 705 cycles of oocyte preservation between 
2010 and 2014 in 17 European countries.15 Egg banking is therefore 
the best option for patients who undergo preservation of fertility for 
social reasons, especially those under the age of 35 years, where a 
probability of 85.2% for a live birth can be expected with 15 vitrified 
oocytes.16
Unfortunately, the vitrification of mature oocytes has some lim-
itations. For example, the need for prior hormonal stimulation can 
delay oncological treatments. Moreover, that technique cannot be 
carried out in prepubertal children. Nevertheless, a major advantage 
is the limitation of the transmission of cancer cells when compared 
to ovarian cortex transplantation.17 A prospective cohort study com-
paring oocyte vitrification versus ovarian cortex transplantation for 
the preservation of fertility in adult women undergoing gonadotoxic 
treatments has shown that live birth rates might be better in the 
oocyte vitrification group. Moreover, the vitrification of oocytes is 
a less burdensome intervention to undertake and is less intrusive.18 
However, the banking of ovarian tissue is an acceptable technique 
of fertility preservation and is no longer considered experimental.
Today, the banking of ovarian tissue remains the only method to 
preserve fertility in prepubertal girls since ovarian stimulation and 
in vitro fertilization (IVF) are not options, as recently reported by 
Dolmans et al.19
4.1  |  Ovarian stimulation protocols
Prior COS is needed to obtain several mature oocytes for 
cryopreservation.
Assessment of a woman's ovarian reserve is a prerequisite to 
maximize the efficacy of the retrieval of oocytes and to limit the risk 
of ovarian hyperstimulation syndrome (OHSS). It cannot predict the 
outcome of the vitrified oocytes but is useful in counseling patients, 
helping to develop realistic expectations, and choosing a safe and 
effective protocol for ovarian stimulation for cancer patients under-
going preservation of fertility.20 Ovarian reserve is routinely per-
formed by one or more of the following three markers: antral follicle 
count (AFC) by ultrasonography; level of anti- Müllerian hormone 
(AMH); and level of early follicle- stimulating hormone (FSH). In the 
case of preservation of fertility, AMH and AFC are the more fre-
quently used markers because their levels vary only slightly during 
the menstrual cycle 20- 22 and are less affected by the oral contracep-
tives frequently administered in young patients compared to levels 
of FSH, although an underestimation of about 30% can be achieved 
with this type of contraception.23
In most cases, administration of GnRH antagonists is used to 
prevent unwanted surges of luteinizing hormone (LH) during COS. 
When compared to GnRH agonist, the antagonist allows the time 
of COS to shorten and the risk of OHSS to be reduced, as ovulation 
triggered by human chorionic gonadotropin (hCG) can be replaced 
by the administration of GnRH agonists.21
For non- oncological patients, COS is initiated on day 2 or 3 in a 
spontaneous cycle by daily injection of 150 to 300 IU of recombi-
nant FSH or highly purified human menopausal gonadotropins (hMG). 
On day 6, the dosage of gonadotropins is re- evaluated according 
to the levels of serum estradiol (E2) and follicular count assessed 
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by transvaginal ultrasound scan. When a leading follicle reaches 
14 mm, the GnRH antagonist is administered.24 Final maturation of 
oocytes is triggered by 250 mg of recombinant hCG or with 0.1 to 
0.2 mg of GnRH agonist triptorelin in case of a high risk of OHSS.16,24 
Ultrasound- guided transvaginal retrieval of ova is scheduled 36 hours 
after the trigger, as performed in the conventional IVF program.
In hormone- dependent patients with cancer, conventional COS 
with gonadotropins must be adapted to limit the rise of the level 
of serum E2. A high level of E2 could promote tumoral growth in 
estrogen- sensitive cancers, such as endometrial and estrogen- 
receptor- positive breast cancers.20 In these cases, letrozole, an aro-
matase inhibitor, can be used (5 mg/day) from day 2 or 3 of cycle 
until the day of triggering. Gonadotropins are started 2 days after 
letrozole, a GnRH antagonist is administered when the leading fol-
licle reaches 14 mm, and final maturation of the oocyte is triggered 
with 0.2 mg of the GnRH agonist triptorelin as soon as two follicles 
are 20 mm or greater.24 Until recently, the outcome of the safety 
of administration of letrozole on IVF children was unclear. A recent 
study published in 2016 provides reassuring data on this subject. 
One study shows that letrozole significantly decreases the risk of 
miscarriage and does not increase the risk of major congenital anom-
alies, adverse pregnancy, or neonatal outcomes when compared 
with natural cycles in patients undergoing antiretroviral therapy.25
In oncological patients, time is a limiting factor preventing the 
use of conventional COS in a subsequent menstrual cycle. Increasing 
evidence indicates that multiple waves of recruitment of antral fol-
licles arise during the human menstrual cycle.26 Therefore, it does 
not seem mandatory to start a COS on day 2 or 3. Based on this con-
cept, a “random start” protocol has been proposed, in which ovarian 
stimulation can be started at any time during the cycle. One possibil-
ity is to administer a GnRH antagonist (0.25 mg/day) for 3 days after 
measuring the levels of serum E2. If the level of E2 is under 60 pg/
mL, COS can be started regardless of menstruation. If the level is 
higher, an extra dose of the GnRH antagonist is given before the 
start of COS.24
Other stimulation protocols exist depending on the phase of 
the cycle, including in the late follicular and even luteal phases20 
(Figure 1).
In the late follicular phase – after day 7 when the dominant fol-
licle is present – the induction of ovulation can be performed if the 
leading follicle is already 14 mm or larger, with possibly a first mono- 
follicular retrieval, followed by luteal phase stimulation.27 If the lead-
ing follicle is smaller than 14 mm, doses of gonadotropins alone are 
started, and the GnRH antagonist is added later when follicles reach 
14 mm or larger to prevent a premature, secondary surge of LH.
All these types of stimulation end like the conventional antag-
onist COS protocol where the administration of gonadotropins and 
GnRH antagonists is continued until the final maturation of the 
oocytes triggered by hCG or GnRH agonist.20 Data show similar 
outcomes whatever the phase of the menstrual cycle chosen for 
the startup of COS.28,29 Moreover, clinical, obstetric, and perinatal 
outcomes seem unaltered depending on the phase of stimulation. 
Indeed, a recent multicenter study comparing these outcomes after 
a single blastocyst transfer obtained from 182 patients after follic-
ular phase stimulation to 207 patients after luteal phase stimulation 
showed the same results for both groups.30
Mature oocytes retrieved are conserved by vitrification. 
Fertilization of the thawed oocytes must be performed by 
F I G U R E  1  Examples of conventional, hormone- dependent, and Random Start stimulation cycles for the cryopreservation of oocytes. 
Inspired and modified from von Wolff et al.27 Abbreviations: foll, follicle; GnRH- ant, gonadotropin- releasing hormone antagonist; IVF, in 
vitro fertilization
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intracytoplasmic spermatozoa injection due to hardening of the zona 
pellucida.
4.2  |  Pregnancy rate after the 
preservation of oocytes
The vitrification of oocytes is a routine effective tool in assisted 
reproduction. Several thousands of pregnancies have already been 
reported with obstetrical and neonatal outcomes similar to those 
obtained with fresh oocytes.16
The survival rate of oocytes, pregnancy, and cumulative live birth 
rates (CLBRs) are highly dependent on the patient's age at the time 
of vitrification and the number of oocytes in storage.16 The probabil-
ity of childbearing is significantly lowered over the age of 35 years. 
Caution should therefore be exercised when counseling patients, 
despite the excellent data obtained from donor oocyte programs 
where the survival rate can exceed 95%.16 A recent publication 
demonstrated that live birth rates were significantly higher in the 
group with preservation of fertility indicated by benign conditions 
compared to oncological reasons (21% vs 47%) but women in the 
oncological group were significantly older when attempting preg-
nancy.31 A retrospective multicentric study of more than 8000 cy-
cles published in 2018 32 showed a lower rate of success in patients 
with cancer when compared to age- banking indications. However, 
there was no statistically significant association between malignant 
disease and reproductive outcome after correction for age and COS 
regimen.32
4.3  |  Limitations of the 
cryopreservation of oocytes
The main limitations of oocyte cryopreservation are the risks of 
OHSS during stimulation, the time required for COS, and the poor 
CLBR in older women.
The prevalence of OHSS is approximately 3% to 8% per COS. In 
its most severe form, OHSS is associated with hemoconcentration, 
ascites, liver dysfunction, pulmonary edema, electrolyte imbalance, 
and thromboembolic events. The COS protocol must be personal-
ized to avoid OHSS, especially in patients with cancer where the 
risk of thromboembolic events is already increased by the neoplasm 
itself. Occurrence of OHSS could also delay the oncological treat-
ment. Therefore, optimal customization of the stimulation regimen 
according to the patient's ovarian reserve is necessary to maxi-
mize the number of oocytes collected while minimizing the risk of 
OHSS.20
Despite the use of a modified COS and the advent of the "ran-
dom start" protocol, a delay of approximately 2 weeks is still nec-
essary for the completion of COS before the retrieval of oocytes. 
Unfortunately, delaying oncological treatments is not always pos-
sible. In this case, cryopreservation of ovarian tissue could be sug-
gested. Another option is in vitro maturation (IVM) of oocytes, as 
discussed below.
Finally, age is a limiting factor in the cryopreservation of oo-
cytes. This technique cannot be used in prepubertal children. 
Moreover, the CLBR falls dramatically with patient aged above 
35 years.
F I G U R E  2  Different options and possibilities for the preservation of fertility for malignant and benign diseases, social and personal 
reasons, and oocyte donation. Abbreviations: IVF, in vitro fertilization; IVM, in vitro maturation
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4.4  |  Possibility of cryopreservation of embryos
The freezing of embryos is an option for the preservation of fertility 
in postpubertal women involved in a stable relationship. It is not ap-
plicable to single or homosexual patients, even if the use of a sperm 
donor remains possible. However, this option can become problem-
atic in case the couple separate.
4.5  |  Particular case: in vitro maturation of oocytes
Another way to preserve fertility when a complete COS cannot be 
achieved due to time constraints is IVM of germinal vesicles into meta-
phase II oocytes (MII). According to Seang Lin Tan, an IVM cycle could be 
defined as any collection cycle of eggs where the majority of the oocytes 
obtained should be at the germinal vesicle stage.21 There is no or minimal 
need for ovarian stimulation, but it seems that an hCG trigger 36 hours 
before the retrieval of oocytes remains necessary.21 In practice, IVM is 
mainly proposed to patients with polycystic ovaries at high risk of OHSS.
IVM is not yet a routine technique for the preservation of fer-
tility. In 2016, Yin et al.33 published a study on the maturation rate 
of immature oocytes aspired from ovarian medulla tissue discarded 
during ovarian cortex dissection. Despite a low rate of maturation, 
the authors suggest that this add- on method could potentially in-
crease the fertility outcome in women with cancer.33 Another study 
of 119 patients with cancer showed a high rate of maturation among 
oocytes retrieved by transvaginal ultrasound- guided aspiration just 
before ovarian tissue sampling. However, the reproductive out-
comes were poor,34 with low numbers of embryos, a low rate of im-
plantation, and a high rate of miscarriage.
5  |  CONCLUSION
Over the last few decades, survival rates in girls and young women 
with cancer have increased significantly. Unfortunately, anticancer 
treatments may alter ovarian function and lead to POI. For such 
patients, the fertility preservation program was developed to allow 
them to conceive after recovery with their own gametes. This con-
cept of the preservation of fertility also concerns patients who are 
at risk of developing ovarian failure and even healthy patients who 
want to prevent age- related exhaustion of gametes.
Two main procedures allow the preservation of fertility in 
women, regardless of the presence of a partner: vitrification of oo-
cytes and cryopreservation of ovarian tissue. Even though the num-
ber of births achieved after self- transplantation of cryopreserved 
ovarian tissue strips has increased exponentially in recent years,35 
the vitrification of oocytes must be the first choice in postpubertal 
women (Figure 2).
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